Literature DB >> 29232539

How to Identify and Manage Cognitive Dysfunction After Breast Cancer Treatment.

Marie Lange1, Florence Joly1.   

Abstract

Attention and memory dysfunction is a common complaint among patients with breast cancer that can be reported during and up to several years after treatment. It can negatively affect patients' quality of life and their ability to work. This phenomenon has mainly been studied in patients with breast cancer who are treated with adjuvant chemotherapy. Women describe concentration problems and difficulties with word finding, multitasking, or remembering new information, as well as more effort and time needed to accomplish these tasks. Such cognitive dysfunction is subtle or moderate and occurs in 15% to 25% of patients. Older patients seem more likely to experience cognitive decline with chemotherapy than do young women with breast cancer. Patients who report that cognitive dysfunction has affected their daily lives for 6 to 12 months after the end of chemotherapy or during hormone therapy may need referral to a neuropsychologist. During the cognitive assessment, the etiology of their cognitive complaints is sought and neuropsychological tests are administered to assess objective cognitive functioning. Psychological factors-fatigue and pain-should be assessed systematically with cognitive complaints to identify precisely the cause of the problems. A nonpharmacologic approach-mainly cognitive rehabilitation-seems to be the most promising for the management of these difficulties, but these preliminary results require confirmation. In the future, early detection of cognitive impairment and cognitive rehabilitation should be included in the portfolio of oncology supportive care to facilitate the return to work of young women and to avoid potential repercussions on adherence to oral treatments and on autonomy in older patients.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 29232539     DOI: 10.1200/JOP.2017.026286

Source DB:  PubMed          Journal:  J Oncol Pract        ISSN: 1554-7477            Impact factor:   3.840


  11 in total

1.  The relationship between diet and cognitive function in adult cancer survivors: a systematic review.

Authors:  Daniel Coro; Amanda Hutchinson; Sophie Dahlenburg; Siobhan Banks; Alison Coates
Journal:  J Cancer Surviv       Date:  2019-08-09       Impact factor: 4.442

2.  Effects of Baduanjin exercise on cognitive function and cancer-related symptoms in women with breast cancer receiving chemotherapy: a randomized controlled trial.

Authors:  Xiaolin Wei; Ruzhen Yuan; Juan Yang; Wei Zheng; Yongmei Jin; Mingyue Wang; Jieting Jiang; Caiqin Wu; Kunpeng Li
Journal:  Support Care Cancer       Date:  2022-04-13       Impact factor: 3.603

3.  Experiences of pelvic floor dysfunction and treatment in women with breast cancer: a qualitative study.

Authors:  Udari N Colombage; Kuan-Yin Lin; Sze-Ee Soh; Robyn Brennen; Helena C Frawley
Journal:  Support Care Cancer       Date:  2022-07-05       Impact factor: 3.359

4.  Cognitive Changes After Adjuvant Treatment in Older Adults with Early-Stage Breast Cancer.

Authors:  Marie Lange; Natacha Heutte; Sabine Noal; Olivier Rigal; Jean-Emmanuel Kurtz; Christelle Lévy; Djelila Allouache; Chantal Rieux; Johan Lefel; Bénédicte Clarisse; Alexandra Leconte; Corinne Veyret; Philippe Barthélémy; Nadine Longato; Laure Tron; Hélène Castel; Francis Eustache; Bénédicte Giffard; Florence Joly
Journal:  Oncologist       Date:  2018-06-22

5.  Development and Validation of a Predictive Model of Severe Fatigue After Breast Cancer Diagnosis: Toward a Personalized Framework in Survivorship Care.

Authors:  Antonio Di Meglio; Julie Havas; Davide Soldato; Daniele Presti; Elise Martin; Barbara Pistilli; Gwenn Menvielle; Agnes Dumas; Cecile Charles; Sibille Everhard; Anne-Laure Martin; Charles Coutant; Carole Tarpin; Laurence Vanlemmens; Christelle Levy; Olivier Rigal; Suzette Delaloge; Nancy U Lin; Patricia A Ganz; Ann H Partridge; Fabrice André; Stefan Michiels; Ines Vaz-Luis
Journal:  J Clin Oncol       Date:  2022-01-21       Impact factor: 44.544

6.  Cognitive complaints in cancer survivors and expectations for support: Results from a web-based survey.

Authors:  Marie Lange; Idlir Licaj; Bénédicte Clarisse; Xavier Humbert; Jean-Michel Grellard; Laure Tron; Florence Joly
Journal:  Cancer Med       Date:  2019-03-18       Impact factor: 4.452

7.  PONDx: real-life utilization and decision impact of the 21-gene assay on clinical practice in Italy.

Authors:  Francesco Cognetti; Riccardo Masetti; Alessandra Fabi; Giulia Bianchi; Donatella Santini; Alessia Rognone; Giovanna Catania; Domenico Angelucci; Giuseppe Naso; Mario Giuliano; Lucia Vassalli; Patrizia Vici; Giovanni Scognamiglio; Daniele Generali; Alberto Zambelli; Marco Colleoni; Corrado Tinterri; Francesco Scanzi; Leonardo Vigna; Paola Scavina; Teresa Gamucci; Emilia Marrazzo; Angelo Fedele Scinto; Rossana Berardi; Maria Agnese Fabbri; Graziella Pinotti; Daniela Franco; Daniela Andreina Terribile; Giuseppe Tonini; Daniela Cianniello; Sandro Barni
Journal:  NPJ Breast Cancer       Date:  2021-05-05

8.  Doxorubicin induces dysregulation of AMPA receptor and impairs hippocampal synaptic plasticity leading to learning and memory deficits.

Authors:  Ahmad H Alhowail; Priyanka D Pinky; Matthew Eggert; Jenna Bloemer; Lauren N Woodie; Manal A Buabeid; Subhrajit Bhattacharya; Shanese L Jasper; Dwipayan Bhattacharya; Muralikrishnan Dhanasekaran; Martha Escobar; Robert D Arnold; Vishnu Suppiramaniam
Journal:  Heliyon       Date:  2021-07-01

Review 9.  Are Sleep Complaints Related to Cognitive Functioning in Non-Central Nervous System Cancer? A Systematic Review.

Authors:  Mylène Duivon; Bénédicte Giffard; Béatrice Desgranges; Joy Perrier
Journal:  Neuropsychol Rev       Date:  2021-08-05       Impact factor: 6.940

10.  The role of metamemory on cognitive complaints in cancer patients.

Authors:  Bénédicte Giffard; Audrey Perrotin; Philippe Allain; Jacques Dayan; Francis Eustache; Jean-Michel Grellard; Audrey Faveyrial; Florence Joly; Marie Lange
Journal:  Brain Behav       Date:  2020-03-10       Impact factor: 2.708

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.